Amioka T, Kitadai Y, Tanaka S, et al. Vascular endothelial growth factor-C expression predicts lymph node metastasis of human gastric carcinomas invading the submucosa. Eur J Cancer. 2002;38:1413–19. [PubMed] [Google Scholar]
Andre T, Kotelevets L, Vaillant JC, et al. Vegf, Vegf-B, Vegf-C and their receptors KDR, FLT-1 and FLT-4 during the neoplastic progression of human colonic mucosa. Int J Cancer. 2000;86:174–81. [PubMed] [Google Scholar]
Awada A, de Castro G., Jr An integrated approach for tailored treatment in breast cancer. Ann Oncol. 2005;16:203–8. [PubMed] [Google Scholar]
Baldwin ME, Catimel B, Nice EC, et al. The specificity of receptor binding by vascular endothelial growth factor-D is different in mouse and man. J Biol Chem. 2001;276:19166–71. [PubMed] [Google Scholar]
Bellomo D, Headrick JP, Silins GU, et al. Mice lacking the vascular endothelial growth factor-B gene (Vegfb) have smaller hearts, dysfunctional coronary vasculature, and impaired recovery from cardiac ischemia. Circ Res. 2000;86:29–35. [PubMed] [Google Scholar]
Bottaro DP, Liotta LA. Cancer: Out of air is not out of action. Nature. 2003;423:593–5. [PubMed] [Google Scholar]
Boehm T, Folkman J, Browder T, et al. Antiangiogenic therapy of experimental cancer does not induce acquired drug resistance. Nature. 1997;390:404–7. [PubMed] [Google Scholar]
Boocock CA, Charnock-Jones DS, Sharkey AM, et al. Expression of vascular endothelial growth factor and its receptors flt and KDR in ovarian carcinoma. J Natl Cancer Inst. 1995;87:506–16. [PubMed] [Google Scholar]
Brenner B, Ilson DH, Minsky BD. Treatment of localized esophageal cancer. Semin Oncol. 2004;31:554–65. [PubMed] [Google Scholar]
Claesson-Welsh L, Welsh M, Ito N, et al. Angiostatin inducesendothelial cells apoptosis and activation of focal adhesion kinase independently of the integrin-binding motif RGD. Proc Natl Acad Sci U S A. 1998;95:5579–83. [PMC free article] [PubMed] [Google Scholar]
Cobleigh MA, Langmuir VK, Sledge GW, et al. A phase I/II dose-escalation trial of bevacizumab in previously treated metastatic breast cancer. Semin Oncol. 2003;30:117–24. [PubMed] [Google Scholar]
Conn G, Bayne ML, Soderman DD, et al. Amino acid and cDNA sequence of a vascular endothelial cell mitogen that is homologous to platelet-derived growth factor. Proc Natl Acad Sci U S A. 1990;87:2628–32. [PMC free article] [PubMed] [Google Scholar]
Dameron KM, Volpert OV, Tainsky MA, et al. Control of angiogenesis in fibroblasts by p53 regulation of thorombospongin-1. Science. 1994;265:1582–4. [PubMed] [Google Scholar]
Decaussin M, Sartelet H, Robert C, et al. Expression of vascular endothelial growth factor (VEGF) and its two receptors (VEGF-R1-Flt1 and VEGF-R2-Flk1/KDR) in non-small cell lung carcinomas (NSCLCs): Correlation with angiogenesis and survival. J Pathol. 1999;188:369–77. [PubMed] [Google Scholar]
Denekamp J. Angiogenesis, neovascular proliferation and vascular pathophysiology as targets for cancer therapy. Br J Radiol. 1993;66:181–96. [PubMed] [Google Scholar]
Dhanabal M, Ramchandran R, Volk R, et al. Endostatin: yeast production, mutants, and antitumor effecting renal cell carcinoma. Cancer Res. 1999;59:189–97. [PubMed] [Google Scholar]
Dvorak HF. Vascular permeability factor/vascular endothelial growth factor: a critical cytokine in tumor angiogenesis and a potential target for diagnosis and therapy. J Clinl Oncol. 2002;20:4368–80. [PubMed] [Google Scholar]
Enholm B, Paavonen K, Ristimaki A, et al. Comparison of VEGF, VEGF-B, VEGF-C and Ang-1 mRNA regulation by serum, growth factors, oncoproteins and hypoxia. Oncogene. 1997;14:2475–83. [PubMed] [Google Scholar]
Evans DB. Preoperative chemoradiation for pancreatic cancer. Semin Oncol. 2005;32:25–9. [PubMed] [Google Scholar]
Ferrara N, Jakeman L, Houck K, et al. Molecular and biological properties of the vascular endothelial growth factor family of proteins. Endocr Rev. 1992;13:18–32. [PubMed] [Google Scholar]
Ferrara N. Vascular endothelial growth factor. Eur J Cancer. 1996;32:2413–22. [PubMed] [Google Scholar]
Folkman J. Tumor angiogenesis theraperutic implications. N Engl J Med. 1971;285:1182–6. [PubMed] [Google Scholar]
Folkman J. What is the evidence that tumors are angiogenesis dependent? J Natl Cancer Inst. 1990;82:4–6. [PubMed] [Google Scholar]
Folkman J. Angiogenesis in cancer, vascular, rheumatoid and other disease. Nat Med. 1995a;1:27–31. [PubMed] [Google Scholar]
Folkman J. Seminars in medicine of the Beth Israel Hospital, Boston. Clinical applications of research on angiogenesis. N Engl J Med. 1995b;333:1757–63. [PubMed] [Google Scholar]
Furudoi A, Tanaka S, Haruma K, et al. Clinical significance of vascular endothelial growth factor C expression and angiogenesis at the deepest invasive site of advanced colorectal carcinoma. Oncology. 2002;62:157–66. [PubMed] [Google Scholar]
George ML, Tutton MG, Janssen F, et al. VEGF-A, VEGF-C, and VEGF-D in colorectal cancer progression. Neoplasia. 2001;3:420–7. [PMC free article] [PubMed] [Google Scholar]
Goldberg RM. Advances in the treatment of metastatic colorectal cancer. Oncologist. 2005;10(Suppl 3):40–8. [PubMed] [Google Scholar]
Gunningham SP, Currie MJ, Han C, et al. The short form of the alternatively spliced flt-4 but not its ligand vascular endothelial growth factor C is related to lymph node metastasis in human breast cancers. Clin Cancer Res. 2000;6:4278–86. [PubMed] [Google Scholar]
Hashimoto I, Kodama J, Seki N, et al. Vascular endothelial growth factor-C expression and its relationship to pelvic lymph node status in invasive cervical cancer. Br J Cancer. 2001;85:93–7. [PMC free article] [PubMed] [Google Scholar]
Hirai M, Nakagawara A, Oosaki T, et al. Expression of vascular endothelial growth factors (VEGF-A/VEGF-1 and VEGF-C/VEGF-2) in postmenopausal uterine endometrial carcinoma. Gynecol Oncol. 2001;80:181–8. [PubMed] [Google Scholar]
Holmgren L, O'Reilly MS, Folkman J. Dormancy of micrometastases: balance proliferation and apoptosis in the presence of angiogenesis suppression. Nat Med. 1995;1:149–53. [PubMed] [Google Scholar]
Hurwitz H, Fehrenbacher L, Novotny W, et al. Bevacizumab plus Irinotecan, Fluorouracil, and Leucovorin for Metastatic Colorectal Cancer. N Eng J Med. 2004;350:2335–42. [PubMed] [Google Scholar]
Inai T, Mancuso M, Hashizume H, et al. Inhibition of vascular endothelial growth factor (VEGF) signaling in cancer causes loss of endothelial fenestrations, regression of tumor vessels, and appearance of basement membrane ghosts. Am J Pathol. 2004;165:35–52. [PMC free article] [PubMed] [Google Scholar]
Izumi Y, Xu L, di Tomaso E, et al. Tumour biology: herceptin acts as an anti-angiogenic cocktail. Nature. 2002;416:279–80. [PubMed] [Google Scholar]
Jain RK. Vascular and interstitial biology of tumors. In: Abeloff M, editor. Clinical oncology. 3rd ed. Philadelphia: Elsevier; 2004. pp. 153–72. [Google Scholar]
Jemal A, Murray T, Ward E, et al. Cancer statistics. CA Cancer J Clin. 2005;55:10–30. [PubMed] [Google Scholar]
Joukov V, Kumar V, Sorsa T, et al. A recombinant mutant vascular endothelial growth factor-C that has lost vascular endothelial growth factor receptor-2 binding, activation, and vascular permeability activities. J Biol Chem. 1998;20:6599–602. [PubMed] [Google Scholar]
Jussila L, Valtola R, Partanen TA, et al. Lymphatic endothelium and Kaposi sarcoma spindle cells detected by antibodies against the vascular endothelial growth factor receptor-3. Cancer Res. 1998;58:1599–604. [PubMed] [Google Scholar]
Kajita T, Ohta Y, Kimura K, et al. The expression of vascular endothelial growth factor C and its receptors in non-small cell lung cancer. Br J Cancer. 2001;85:255–60. [PMC free article] [PubMed] [Google Scholar]
Kirsch M, Strasser J, Allende R, et al. Angiogenesis suppresses malignant glioma growth in vivo. Cancer Res. 1998;58:4654–9. [PubMed] [Google Scholar]
Kiba A, Sagara H, Hara T, et al. VEGFR-2-specific ligand VEGF-E induces non-edematous hyper-vascularization in mice. Biochem Biophys Res Commun. 2003;301:371–7. [PubMed] [Google Scholar]
Kim RY, Omura GA, Alvarez RD. Advances in the treatment of gynecologic malignancies. Part 2: Cancers of the uterine corpus and ovary. Oncology. 2002;16:1669–80. [PubMed] [Google Scholar]
Kinoshita J, Kitamura K, Kabashima A, et al. Clinical significance of vascular endothelial growth factor-C (VEGF-C) in breast cancer. Breast Cancer Res Treat. 2001;66:159–64. [PubMed] [Google Scholar]
Kurebayashi J, Otsuki T, Kunisue H, et al. Expression of vascular endothelial growth factor (VEGF) family members in breast cancer. Jpn J Cancer Res. 1999;90:977–81. [PMC free article] [PubMed] [Google Scholar]
Lee CG, Heijn M, di Tomaso E, et al. Anti-Vascular endothelial growth factor treatment augments tumor radiation response under normoxic or hypoxic conditions. Cancer Res. 2000;60:5565–70. [PubMed] [Google Scholar]
Leung DW, Cachianes G, Kuang WJ, et al. Vascular endothelial growth factor is a secreted angiogenic mitogen. Science. 1989;246:1306–9. [PubMed] [Google Scholar]
Lin J, Beerm DG. Molecular biology of upper gastrointestinal malignancies. Semin Oncol. 2004;31:476–86. [PubMed] [Google Scholar]
Long HJ., 3rd Current research directions for locally advanced cervix cancer. Curr Oncol Rep. 2003;5:468–72. [PubMed] [Google Scholar]
Lucas R, Holmgren L, Garcia I, et al. Multiple forms of angiostatin induce apoptosis in endothelial cells. Blood. 1998;92:4730–41. [PubMed] [Google Scholar]
Lyttle DJ, Fraser KM, Fleming SB, et al. Homologs of vascular endothelial growth factor are encoded by the poxvirus orf virus. J Virol. 1994;68:84–92. [PMC free article] [PubMed] [Google Scholar]
Ma J, Pulfer S, Li S, et al. Pharmacodynamic-mediated reduction of temozolomide tumor concentrations by the angiogenesis inhibitor TNP-470. Cancer Res. 2001;61:5491–8. [PubMed] [Google Scholar]
Maisonpierre PC, Suri C, Jones PF, et al. Angiopoietin-2, a natural antagonist for Tie2 that disrupts in vivo angiogenesis. Science. 1997;277:55–60. [PubMed] [Google Scholar]
Majima M, Hayashi I, Muramatsu M, et al. Cyclo-oxygenase-2 enhances basic fibrobrast growth factor-induced angiogenesis through induction o vascular endothelial growth factor in rat sponge implants. Br J Pharmacol. 2000;268:641–9. [PMC free article] [PubMed] [Google Scholar]
Mandriota SJ, Jussila L, Jeltsch M, et al. Vascular endothelial growth factor-C-mediated lymphangiogenesis promotes tumour metastasis. EMBO J. 2001;20:672–82. [PMC free article] [PubMed] [Google Scholar]
Mayer RJ. Two steps forward in the treatment of colorectal cancer. N Engl J Med. 2004;350:2406–8. [PubMed] [Google Scholar]
Migdal M, Huppertz B, Tessler S, et al. Neuropilin-1 is a placenta growth factor-2 receptor. J Biol Chem. 1998;273:22272–8. [PubMed] [Google Scholar]
Mizejewski GJ. Role of integrins in cancer: survey of expression patterns. Proc Soc Exp Biol Med. 1999;222:124–38. [PubMed] [Google Scholar]
Muthukkaruppan VR, Kubai L, Auerbach R. Tumor-induced neovascularization in the mouse eye. J Natl Cancer Inst. 1982;69:699–708. [PubMed] [Google Scholar]
Nelson AR, Fingleton B, Rothenberg ML, et al. Matrix metalloproteinases: biologic activity and clinical implications. J Clin Oncol. 2000;18:1135–49. [PubMed] [Google Scholar]
Neufeld G, Cohen T, Gengrinovitch S, et al. Vascular endothelial growth factor (VEGF) and its receptors. FASEB J. 1999;13:9–22. [PubMed] [Google Scholar]
Niki T, Iba S, Tokunou M, et al. Expression of vascular endothelial growth factor A, B, C, and D and their relationships to lymph node status in lung adenocarcinoma. Clin Cancer Res. 2000;6:2431–9. [PubMed] [Google Scholar]
Nishida N, Yano H, Komai K, et al. Vascular endothelial growth factor C and vascular endothelial growth factor receptor 2 are related closely to the prognosis of ovarian carcinoma. Cancer. 2004;101:1364–74. [PubMed] [Google Scholar]
O-charoenrat P, Rhys-Evans P, Eccles SA. Expression of vascular endothelial growth factor family members in head and neck squamous cell carcinoma correlates with lymph node metastasis. Cancer. 2001;92:556–68. [PubMed] [Google Scholar]
Ogawa S, Oku A, Sawano A, et al. A novel type of vascular endothelial growth factor, VEGF-E (NZ-7 VEGF), preferentially utilizes KDR/Flk-1 receptor and carries a potent mitotic activity without heparin-binding domain. J Biol Chem. 1998;273:31273–82. [PubMed] [Google Scholar]
Ohta Y, Shridhar V, Bright RK, et al. VEGF and VEGF type C play an important role in angiogenesis and lymphangiogenesis in human malignant mesothelioma tumours. Br J Cancer. 1999;81:54–61. [PMC free article] [PubMed] [Google Scholar]
Olsson AK, Johansson I, ?kerud H, et al. The minimal active domain of endostatin is a heparin-binding motif that mediates inhibition of tumor vascularization. Cancer Res. 2004;64:9012–17. [PubMed] [Google Scholar]
Olofsson B, Pajusola K, Kaipainen A, et al. Vascular endothelial growth factor B, a novel growth factor for endothelial cells. Proc Natl Acad Sci U S A. 1996;93:2576–81. [PMC free article] [PubMed] [Google Scholar]
O'Reilly MS, Boehm T, Shing Y, et al. Endostatin: an endogenous inhibitor of angiogenesis and tumor growth. Cell. 1997;88:277–85. [PubMed] [Google Scholar]
Orlandini M, Marconcini L, Ferruzzi R, et al. Identification of a c-fos-induced gene that is related to the platelet-derived growth factor/vascular endothelial factor family. Proc Natl Acad Sci U S A. 1996;93:11675–80. [PMC free article] [PubMed] [Google Scholar]
Padera TP, Stoll BR, Tooredman JB, et al. Pathology: cancer cells compress intratumour vessels. Nature. 2004;427:695. [PubMed] [Google Scholar]
Pfister DG, Johnson DH, Azzoli CG, et al. American Society of Clinical Oncology treatment of unresectable non-small-cell lung cancer guideline: updated 2003. J Clin Oncol. 2004;22:330–53. [PubMed] [Google Scholar]
Parangi S, O'Reilly M, Christofori G, et al. Angiogenesis therapy of transgenic mice impairs de novo tumor growth. Proc Natl Acad Sci U S A. 1996;93:2002–7. [PMC free article] [PubMed] [Google Scholar]
Peeper MS. Lymphangiogensis and tumor metastasis: Myth or reality? Clin Cancer Res. 2001;7:462–8. [PubMed] [Google Scholar]
Rakesh KJ. Normalization of tumor vasculature: an emerging concept in antiangiogenic therapy. Science. 2005;307:58–62. [PubMed] [Google Scholar]
Rafii S, Skobe M. Spilitting vessels: Keeping lymph apart from blood. Nature Med. 2003;9:166–8. [PubMed] [Google Scholar]
Rehn M, Veikkola T, Kukk-Valdre E, et al. Interaction of endostatin with integrins implicated in angiogenesis. Proc Natl Acad Sci U S A. 2001;98:1024–9. [PMC free article] [PubMed] [Google Scholar]
Salven P, Lymboussaki A, Heikkila P, et al. Vascular endothelial growth factors VEGF-B and VEGF-C are expressed in human tumors. Am J Pathol. 1998;153:103–8. [PMC free article] [PubMed] [Google Scholar]
Semenza G. Signal transduction to hypoxia-inducible factor 1. Biochem Pharmacol. 2002;64:993–8. [PubMed] [Google Scholar]
Skobe M, Hawighorst T, Jackson DG, et al. Induction of tumor lymphangiogenesis by VEGF-C promotes breast cancer metastasis. Nat Med. 2001;7:192–8. [PubMed] [Google Scholar]
Soker S, Takashima S, Miao HQ, et al. Neuropilin-1 is expressed by endothelial and tumor cells as an isoform-specific receptor for vascular endothelial growth factor. Cell. 1998;92:735–45. [PubMed] [Google Scholar]
Stack MS, Gately S, Bafetti LM, et al. Angiostatin inhibits endothelial and melanoma cellular invasion by blocking matrix-enhanced plasminogen activation. Biochem J. 1999;340:77–84. [PMC free article] [PubMed] [Google Scholar]
Stalmans I, Ng YS, Rohan R, et al. Arteriolar and venular patterning in retinas of mice selectively expressing VEGF isoforms. J Clin Invest. 2002;109:327–36. [PMC free article] [PubMed] [Google Scholar]
Suri C, Jones PF, Patan S, et al. Requisite role of angiopoietin-1, a ligand for the TIE2 receptor, during embryonic angiogenesis. Cell. 1996;87:1171–80. [PubMed] [Google Scholar]
Teicher BA. A systems approach to cancer therapy. (Antioncogenics + standard cytotoxics→mechanism(s) of interaction) Cancer Metastasis Rev. 1996;15:247–72. [PubMed] [Google Scholar]
Tong RT, Boucher Y, Kozin SV, et al. Vascular normalization by vascular endothelial growth factor receptor 2 blockade induces a pressure gradient across the vasculature and improves drug penetration in tumors. Cancer Res. 2004;64:3731–6. [PubMed] [Google Scholar]
Tournaire R, Simon MP, le Noble F, et al. A short synthetic peptide inhibits signal transduction, migration and angiogenesis mediated by Tie2 receptor. EMBO Rep. 2004;5:262–7. [PMC free article] [PubMed] [Google Scholar]
Vincenti V, Cassano C, Rocchi M, et al. Assignment of the vascular endothelial growth factor gene to the human chromosome 6q21.3. Circulation. 1996;93:1493–5. [PubMed] [Google Scholar]
Wickstrom SA, Alitalo K, Keski-Oja J. Endostatin associates with integrin alfa5beta1 and caveolin-1, and activates Src via a tyrosyl phosphatasa-dependent pathway in human endothelial cells. Cancer Res. 2002;62:5580–9. [PubMed] [Google Scholar]
Willett CG, Boucher Y, di Tomaso E, et al. Direct evidence that the VEGF-specific antibody bevacizumab has antivascular effects in human rectal cancer. Nat Med. 2004;10:145–7. [PMC free article] [PubMed] [Google Scholar]
Winkler F, Kozin SV, Tong RT, et al. Kinetics of vascular normalization by VEGFR2 blockade governs brain tumor response to radiation: role of oxygenation, angiopoietin-1, and matrix metalloproteinases. Cancer Cell. 2004;6:553–63. [PubMed] [Google Scholar]
Yang JC, Haworth L, Sherry RM, et al. A randomized trial of bevacizumab, an anti–vascular endothelial growth factor antibody, for metastatic renal cancer. N Engl J Med. 2003;349:427–34. [PMC free article] [PubMed] [Google Scholar]
Yokoyama Y, Charnock-Jones DS, Licence D, et al. Vascular endothelial growth factor D is an independent prognostic factor on epithelial ovarian carcinoma. Br J Cancer. 2003;88:237–44. [PMC free article] [PubMed] [Google Scholar]
Yonekura H, Sakurai S, Liu X, et al. Placenta growth factor and vascular endothelial growth factor B and C expression in microvascular endothelial cells and pericytes: implication in autocrine and paracrine regulation of angiogenesis. J Biol Chem. 1999;274:35172–8. [PubMed] [Google Scholar]
Yonemura Y, Endo Y, Fujita H, et al. Role of vascular endothelial growth factor C expression in the development of lymph node metastasis in gastric cancer. Clin Cancer Res. 1999;5:1823–9. [PubMed] [Google Scholar]
Yuan F, Chen Y, Dellian M, et al. Time-dependent vascular regression and permeability changes in established human tumor xenografts induced by an anti-vascular endothelial growth factor/vascular permeability factor antibody. Proc Natl Acad Sci U S A. 1996;93:14765–70. [PMC free article] [PubMed] [Google Scholar]